Novartis

Novartis
Fabrikstrasse 2, 4056 Basel
Novartis  
Discipline: Medicine/Pharmacology
Related:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

#display_name

Business - Mar 22
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange Commission Alcon will enter key Swiss SMI and SPI indices on first trading day Alcon's credit rating confirmed as investment grade (Baa2 by Moody's Investor Se
Business - Mar 18

  Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle independence US-based PowerVision, Inc.

Business - Mar 14

Richard Francis, CEO Sandoz, to step down on March 31, 2019 -   Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced today that Richard Francis will be stepping down as CEO of Sandoz, a Novartis division, and as a member of the Executive Committee of Novartis on March 31, 2019.

Pharmacology - Mar 5

New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) -   Results from CLARITY study

Business - Feb 28

Shareholders approve 22 nd consecutive dividend increase to CHF 2.85 (+2%) per share for 2018; representing a 3.1% yield and approximately 57% payout of free cash flow -   Overwhelming majority of shareholders approve proposed 100% spin-off of the Alcon eye care division -   Dr&peri

Business - Feb 25

Basel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019.

Health - Mar 14

Study is planned to assess efficacy and safety of Entresto (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019 -   Chagas disease is a potentially life-threatening neglected disease, affecting approximately six m

Pharmacology - Mar 11

Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and digital therapeutics to address healthcare access challenges Sandoz invited people worldwide to "reimag

Pharmacology - Mar 4

Phase III study shows close to 9/10 patients who received Cosentyx 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3 -   Results strengthen unique position of Cosentyx as a rapid and long-lasting complete tre

Health - Feb 25

Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals, for targeted cardiovascular therapy  -   Novartis is

Pharmacology - Feb 13

Egaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO -   Fascioliasis, commonly known as liver fluke infestation, is estimated to infect 2.4 million people globally -   Novartis has been donating




website preview

Link

Medicine and Life Sciences